Brant Inman

Overview:

Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.

Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers

Positions:

Professor of Surgery

Surgery, Urology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1999

University of Alberta (Canada)

M.D. 2000

University of Alberta (Canada)

M.S. 2011

Mayo Clinic, Alix School of Medicine

Residency, Urology

Universite Laval (Canada)

Fellowship, Urologic Oncology

Mayo Clinic

Grants:

Phase II Trial of Aerobic Training in Metastatic Breast Cancer

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY BLADDER CANCER

Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

Administered By
Surgery, Urology
Role
Principal Investigator
Start Date
End Date

A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON¿MUSCLEINVASIVE BLADDER CANCER

Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

TAR-200 Study

Administered By
Surgery, Urology
Awarded By
TARIS Biomedical, LLC
Role
Principal Investigator
Start Date
End Date

Publications:

Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.

PURPOSE: Renal function outcomes between radical nephroureterectomy (RNU) and nephron-sparing surgery (NSS) for upper tract urothelial carcinoma (UTUC) patients are not well established. We sought to compare the incidence and factors associated with development of advanced chronic kidney disease (CKD) between RNU and NSS and examine the role of acute kidney injury (AKI) on renal function outcomes. METHODS: We retrospectively analyzed an institutional database for patients who underwent either RNU or NSS for UTUC. Cumulative incidence of postoperative advanced CKD, defined as eGFR < 30 ml/min/1.73 m2, was compared between groups. Fine-Gray competing risk regression was used to identify predictors of advanced CKD. Locally weight scatterplot smoothing was used to assess postoperative eGFR trends. AKI events were counted, staged, and assessed for influence of progression to advanced CKD. RESULTS: Four hundred and twenty-six patients were included in analysis, with a median follow up of 6.68 years (IQR 3.4-12.2). Median preoperative eGFR was similar between the groups (NSS: 68 ml/min/1.73 m2, RNU: 65 ml/min/1.73 m2,P = 0.220). Cumulative incidence of advanced CKD was significantly lower in the NSS cohort (P = 0.009). Factors associated with advanced CKD included age, diabetes, recurrent AKI and RNU. Percent of patients with an AKI event differed between the groups (51.5% NSS, 72.7% RNU, P = <0.001), there was no between group difference in percentage of patients with recurrent AKI (25.6% NSS, 25.9% RNU, P =1). CONCLUSION: NSS provides a renal function benefit in UTUC. AKI is common among UTUC patients and recurrent AKI is a risk factor for development of advanced CKD.
Authors
Dudinec, JV; Ortiz-Melo, DI; Lipkin, ME; Abern, MR; Shah, AM; Inman, BA
MLA Citation
Dudinec, John V., et al. “Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.Urol Oncol, Dec. 2022. Pubmed, doi:10.1016/j.urolonc.2022.11.020.
URI
https://scholars.duke.edu/individual/pub1560084
PMID
36526526
Source
pubmed
Published In
Urol Oncol
Published Date
DOI
10.1016/j.urolonc.2022.11.020

Metabolic flexibility in patients undergoing Radical Cystectomy

Authors
Whittle, J; Coleman, D; Molinger, J; Inman, B; MacLeod, DB
MLA Citation
Whittle, John, et al. “Metabolic flexibility in patients undergoing Radical Cystectomy.” Anesthesia and Analgesia, vol. 134, 2022, pp. 971–72.
URI
https://scholars.duke.edu/individual/pub1550973
Source
wos-lite
Published In
Anesthesia and Analgesia
Volume
134
Published Date
Start Page
971
End Page
972

Plasmonic Gold Nanostars for Immuno Photothermal Nanotherapy to Treat Cancers and Induce Long-Term Immunity

Authors
Vo-Dinh, T; Inman, BA; Maccarini, P; Palmer, GM; Liu, Y; Etienne, W
MLA Citation
Vo-Dinh, Tuan, et al. “Plasmonic Gold Nanostars for Immuno Photothermal Nanotherapy to Treat Cancers and Induce Long-Term Immunity.” Bioanalysis, Springer International Publishing, 2021, pp. 173–90. Crossref, doi:10.1007/978-3-030-78338-9_8.
URI
https://scholars.duke.edu/individual/pub1555906
Source
crossref
Published Date
Start Page
173
End Page
190
DOI
10.1007/978-3-030-78338-9_8

Immunotherapy: From Discovery to Bedside

Authors
Shah, A; Grimberg, D; Inman, BA
MLA Citation
Shah, Ankeet, et al. “Immunotherapy: From Discovery to Bedside.” Bioanalysis, Springer International Publishing, 2021, pp. 51–66. Crossref, doi:10.1007/978-3-030-78338-9_3.
URI
https://scholars.duke.edu/individual/pub1555907
Source
crossref
Published Date
Start Page
51
End Page
66
DOI
10.1007/978-3-030-78338-9_3

Urologic Malignancies

Immune checkpoint inhibitors (ICI) have revolutionized the care of urologic malignancies, in particular urothelial carcinoma (UC) and renal cell carcinoma (RCC). Five PD-1/PD-L1 ICIs have been approved for platinum-refractory advanced UC: atezolizumab, pembrolizumab, nivolumab, durvalumab, and avelumab. Atezolizumab and pembrolizumab have also been approved for cisplatin-ineligible advanced UC. For advanced RCC, nivolumab was the first ICI approved in the setting of prior antiangiogenic therapy. The ICI combination of nivolumab with ipilimumab has recently demonstrated improved overall response rate and overall survival in intermediate- and poor-risk patients with treatment-naïve, clear cell metastatic RCC (mRCC) and has become the standard of care. An ICI and vascular endothelial growth factor (VEGF)-targeted therapy combination, atezolizumab and bevacizumab, was randomized against sunitinib in the first-line treatment of mRCC, and this trial recently reported improvement of progression-free survival with the combination in a subset of patients. More ICI-ICI and ICI-VEGF inhibitor combinations are in clinical testing. The development of ICIs in prostate cancer has been challenging, and no ICIs are currently approved; however, progress is being made.
MLA Citation
Harrison, M. R., et al. “Urologic Malignancies.” Immune Checkpoint Inhibitors in Cancer, 2019, pp. 115–33. Scopus, doi:10.1016/B978-0-323-54948-6.00006-8.
URI
https://scholars.duke.edu/individual/pub1547876
Source
scopus
Published Date
Start Page
115
End Page
133
DOI
10.1016/B978-0-323-54948-6.00006-8

Research Areas:

BCG Vaccine
Cancer Vaccines
Carcinoma, Renal Cell
Clinical Trial
Cystectomy
Immunotherapy
Immunotherapy, Adoptive
Kidney Neoplasms
Magnetic nanoparticle hyperthermia
Metastasectomy
Nephrectomy
Penile Neoplasms
Prostate
Prostatic Neoplasms
Testicular Diseases
Testicular Neoplasms
Thermotherapy
Urethral Neoplasms
Urinary Bladder Neoplasms
Urinary Diversion
Urologic Neoplasms
Urology